



2024 American Society of Hematology (ASH) Annual Conference

TAKEDA SPONSORED ABSTRACTS

ABSTRACT #	TITLE	SESSION
------------	-------	---------

CHRONIC MYELOID LEUKEMIA

[ABSTRACT 3148](#)

5-Year Follow-Up of the Phase 2 OPTIC Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results

POSTER PRESENTATION

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II

December 8, 2024
6:00 – 8:00 PM PST

Location: San Diego Convention Center, Halls G-H



PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

[ABSTRACT 2821](#)

Ponatinib Monotherapy After Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 PhALLCON Study

POSTER PRESENTATION

613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster II

December 8, 2024
6:00 – 8:00 PM PST

Location: San Diego Convention Center, Halls G-H



[ABSTRACT 2825](#)

Quality-adjusted Time Without Symptoms of Disease or Toxicity (Q-TWiST) of Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

POSTER PRESENTATION

613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster II

December 8, 2024
6:00 – 8:00 PM PST

Location: San Diego Convention Center, Halls G-H



HODGKIN LYMPHOMA

[ABSTRACT 568](#)

PET-guided BrECADD in Older Patients with Advanced-Stage Classical Hodgkin Lymphoma: The Older Cohort of the International GHSG HD21 Trial

ORAL PRESENTATION*

624. Hodgkin Lymphomas: Clinical and Epidemiological: Optimization of Therapy

December 8, 2024
12:45 PM PST

Location: San Diego Convention Center, Ballroom 20CD



[ABSTRACT 4426](#)

Impact of Treatment-Related Morbidities on Health-Related Quality of Life in Advanced-Stage Classical Hodgkin Lymphoma Receiving Multiagent Therapy: Findings from the HD21 Study

POSTER PRESENTATION

624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster III

December 9, 2024
6:00 – 8:00 PM PST

Location: San Diego Convention Center, Halls G-H



*Study to be presented by the German Hodgkin Study Group (GHSG)

CERTAIN ABSTRACTS MAY RELATE TO DRUGS AND/OR USES THAT ARE INVESTIGATIONAL, AND FOR WHICH SAFETY AND EFFICACY HAVE NOT YET BEEN ESTABLISHED. THIS IS NO GUARANTEE THAT SUCH DRUGS AND/OR USES WILL BE APPROVED



ABSTRACT #

TITLE

SESSION

HODGKIN LYMPHOMA (CONTINUED)[ABSTRACT
2346](#)

Estimation of Health State Utility Values for Patients Undergoing First-line Treatment of Advanced Stage Classical Hodgkin Lymphoma in the HD21 Trial

POSTER PRESENTATION

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I

December 7, 2024
5:30 – 7:30 PM PST

Location: San Diego Convention Center, Halls G-H

[ABSTRACT
1662](#)

Patient-Reported Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced Hodgkin Lymphoma Patients Treated with BrECADD and eBEACOPP in the HD21 Trial

POSTER PRESENTATION

624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster I

December 7, 2024
5:30 – 7:30 PM PST

Location: San Diego Convention Center, Halls G-H

[ABSTRACT
2376](#)

Effectiveness and Safety for Re-Treatment with Brentuximab-Vedotin in Patients with Relapsed/Refractory (R/R) CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain. The BELIEVE Study. NCT:04998331

POSTER PRESENTATION

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I

December 7, 2024
5:30 – 7:30 PM PST

Location: San Diego Convention Center, Halls G-H

[ABSTRACT
4435](#)

BV-CHP in Previously Untreated Patients with CD30-Positive Adult T-Cell Leukemia-Lymphoma: A Multicenter Real-World Retrospective Study

POSTER PRESENTATION

625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster III

December 9, 2024
6:00 – 8:00 PM PST

Location: San Diego Convention Center, Halls G-H

**POLYCYTHEMIA VERA**[ABSTRACT
4559](#)

Final Results from the Phase 2 REVIVE Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)

POSTER PRESENTATION*

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III

December 9, 2024
6:00 – 8:00 PM PST

Location: San Diego Convention Center, Halls G-H



*Supported by Protagonist Therapeutics, Inc., as part of a worldwide license and collaboration agreement for the development and commercialization of rusfertide (TAK-121)

CERTAIN ABSTRACTS MAY RELATE TO DRUGS AND/OR USES THAT ARE INVESTIGATIONAL, AND FOR WHICH SAFETY AND EFFICACY HAVE NOT YET BEEN ESTABLISHED. THIS IS NO GUARANTEE THAT SUCH DRUGS AND/OR USES WILL BE APPROVED



ABSTRACT #	TITLE	SESSION
------------	-------	---------

THROMBOTIC THROMBOCYTOPENIC PURPURA

[ABSTRACT 141](#)

Recombinant ADAMTS13 Prophylaxis in Pediatric Patients with Congenital Thrombotic Thrombocytopenic Purpura: Results from the Phase 3 Randomized, Crossover Study and the Phase 3b Continuation Study

ORAL PRESENTATION

331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: A Brave New World: Novel Tools, Targets and Treatments in TTP

December 7, 2024
12:30 PM PST

Location: San Diego Convention Center, Room 30



[ABSTRACT 4002](#)

Mutation Analysis of the ADAMTS13 Gene in Patients with Congenital Thrombotic Thrombocytopenic Purpura from the rADAMTS13 Phase 3 Study

POSTER PRESENTATION

331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster III

December 9, 2024
6:00 - 8:00 PM PST

Location: San Diego Convention Center, Halls G-H



[ABSTRACT 4006](#)

Pharmacodynamic Activity of Recombinant ADAMTS13 Versus Plasma-Based Therapies in Congenital Thrombotic Thrombocytopenic Purpura: Interim Results of a Phase 3 Randomized, Controlled, Open-Label Study

POSTER PRESENTATION

331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster III

December 9, 2024
6:00 - 8:00 PM PST

Location: San Diego Convention Center, Halls G-H



--

Clinical Outcomes of Immune-Mediated Thrombotic Thrombocytopenic Purpura from a Multinational Patient Population

PUBLICATION ONLY



VON WILLEBRAND DISEASE

[ABSTRACT 2594](#)

Continuous Prophylaxis with Recombinant Von Willebrand Factor in People with Clinically Severe Congenital Types 1 and 2 Von Willebrand Disease in a Real-World Setting: Interim Analysis of ATHN 9, A Natural History Study for People with Severe VWD

POSTER PRESENTATION

323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster II

December 8, 2024
6:00 - 8:00 PM PST

Location: San Diego Convention Center, Halls G-H



--

A Phase 3, Prospective, Open-label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis with Recombinant Von Willebrand Factor in Children Diagnosed with Severe Von Willebrand Disease

PUBLICATION ONLY



ABSTRACT # TITLE SESSION

MULTIPLE MYELOMA

[ABSTRACT 707](#)

Real-World Effectiveness of Immunoglobulin Replacement Therapy on Hypogammaglobulinemia and Infectious Complications in Patients with Multiple Myeloma

ORAL PRESENTATION

907. Outcomes Research: Plasma Cell Disorders: Frailty, Supportive Care, and Factors Impacting Outcomes Hematology Disease Topics & Pathways:

December 8, 2024
5:30 PM PST

Location: Marriott Marquis San Diego Marina, San Diego Ballroom AB



[ABSTRACT 4757](#)

In-class Transition From Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Analysis of US MM-6 by Number of Treatment Cycles Received

POSTER PRESENTATION

654. Multiple Myeloma: Pharmacologic Therapies: Poster III

December 9, 2024
6:00 – 8:00 PM PST

Location: San Diego Convention Center, Halls G-H



MULTIPLE MYELOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA

[ABSTRACT 1857](#)

Incidence of Infections and Survival Outcomes in Patients with Multiple Myeloma and Chronic Lymphocytic Leukemia in Sweden: A Nationwide Population-Based Study of More Than 15,000 Patients

POSTER PRESENTATION

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I

December 7, 2024
5:30 - 7:30 PM PST

Location: Marriott Marquis San Diego Marina, San Diego Ballroom AB



ONCOLOGY EARLY-STAGE DATA

[ABSTRACT 95](#)

Efficacy and Safety of TAK-007, Cord Blood-Derived CD19 CAR-NK Cells, in Adult Patients (Pts) With Relapsed/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)

ORAL PRESENTATION

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: CAR-T Cell Therapies for Lymphomas and ALL: New Strategies and Toxicities

December 7, 2024
10:30 AM PST

Location: Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13



[ABSTRACT 3355](#)

Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)

POSTER PRESENTATION

654. Multiple Myeloma: Pharmacologic Therapies: Poster II

December 8, 2024
6:00 – 8:00 PM PST

Location: San Diego Convention Center, Halls G-H



For more information, please see the [ASH online program](#).